On April 3, 2015, Dennis Mulroy resigned as Chief Financial Officer of Taxus Cardium Pharmaceuticals Group Inc. Mr. Mulroy resigned to pursue other opportunities and did not receive any severance payments under his employment agreement in connection with his departure. Mr. Mulroy's departure is not due to any dispute or disagreement with the company.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -.--% |
2022 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
2021 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 64 | |
+2.45% | 42.75B | |
+47.70% | 41.61B | |
+11.87% | 41.34B | |
-8.83% | 26.59B | |
+7.04% | 25.49B | |
-22.66% | 18.12B | |
+30.65% | 12.24B | |
-1.90% | 11.76B | |
+9.19% | 11B |
- Stock Market
- Equities
- CRXM Stock
- News Gene Biotherapeutics, Inc.
- Dennis Mulroy Resigns as Chief Financial Officer of Taxus Cardium Pharmaceuticals Group Inc on April 3, 2015